Cardiff Oncology

Cardiff Oncology confirmed exclusive worldwide rights to Onvansertib after an agreement with Nerviano and presented convincing phase II data at an investor conference, reporting an overall response rate of 72% for the Onvansertib plus FOLFIRI/Bevacizumab combination. The FDA agreed to a simplified 1:1 randomized phase III design (CRDF‑004) with about 640 patients, with overall response rate as the primary endpoint potentially enabling accelerated approval. The company is targeting a global launch in early 2026 but still needs to secure $128–176 million to fund the trial and is weighing capital‑markets options, non‑dilutive financings and partnerships. » Mere på de.investing.com

Cardiff Oncology completed the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 each in a registered direct offering, yielding gross proceeds of approximately $10 million before fees. Officers and directors purchased 731,707 shares and warrants at $1.435 each; the warrants have an exercise price of $1.31, are exercisable no earlier than six months after issuance or after approval of the equity increase, and expire five and a half years after they first become exercisable. H.C. Wainwright & Co. acted as exclusive placement agent. Cardiff Oncology intends to use the net proceeds for working capital and general corporate purposes. » Mere på de.investing.com

Cardiff Oncology will present preclinical data on its PLK1 inhibitor Onvansertib at the AACR 2026 annual meeting, which are intended to show that Onvansertib enhances the antitumor activity of trastuzumab‑deruxtecan (T‑DXd) and overcomes resistance in treatment‑refractory HER2‑low breast cancer models. Onvansertib is an orally administered PLK1 inhibitor currently being tested in a phase 2 trial in RAS‑mutant metastatic colorectal cancer and is being investigated in additional trials across various tumor types. The poster (abstract no. 329) will be made available on the company’s website after the presentation. » Mere på de.investing.com